Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Eur J Pharm Sci. 2021 Mar 27;162:105821. doi: 10.1016/j.ejps.2021.105821

Fig. 7.

Fig. 7.

Summary of divergent SAR for DYRK1A and MAO-A inhibition by identified harmine analogs. (A) Schematic of core β-carboline structure highlighting R substituents and positions 2, 7 and 9 (in red). (B) Table of substituents, IC50 values for DYRK1A, MAO-A with compounds ranked by inhibition ratio (DYRK1A IC50: MAO IC50) for the harmine analogs.